CNR1 and Obesity: In this context, some researchers wanted to develop CB1R antagonists (including inverse agonists) as a safer alternative in those pathologies having an overactivity of the endocannabinoid system (e.g., obesity, addiction, schizophrenia), although side effects were also evident with such strategy (see below).